KEYTRUDA® (pembrolizumab)
KEYNOTE-177: 5-Year Update with Dr. Kai-Keen Shiu
Prescribing Information [External link]
Dr. Kai-Keen Shiu, Consultant Medical Oncologist at the UCL Cancer Institute and lead investigator in the KEYNOTE-177 trial, summarises data from the 5-year follow-up of the Phase III trial for patients with advanced MSI-H/dMMR mCRC.1
dMMR = Mismatch Repair-Deficient; mCRC = Metastatic Colorectal Cancer; MSI-H = Microsatellite Instability-High
Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).
More information about KEYTRUDA® (pembrolizumab) in metastatic CRC
Reference
- Shiu KK, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study. ESMO. 20–24 October 2023. Madrid, Spain.
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
